Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Department of War, through the Defense Health Agency, is soliciting quotes under RFQ HT9402-26-Q-9304 to establish Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program agreements for newly approved pharmaceutical agents, in compliance with 10 U.S.C. § 1074g and 32 CFR § 199.21. The solicitation targets nine specific drugs scheduled for review by the Pharmacy and Therapeutics Committee in August 2026, including Atoncy for ADHD, Baxfendy for diuretics, Duloxetine for depression, Filkri for white blood cell stimulation, Hepcludex for hepatitis D, Lynavoy for gastrointestinal use, Veppanu for breast cancer, Xocova for COVID-19, and Xtoro for antibiotics. Offerors must submit pricing data for each 11-digit NDC number, with unit prices stated to four decimal places and consistent across all package sizes, alongside clinical and logistical information to support clinical effectiveness and cost-effectiveness evaluations. The selection process is driven by the P&T Committee’s determination of relative clinical benefit and net ingredient cost, directly influencing placement into tiered formulary categories such as Basic Core, Extended Core, or Non-formulary, with Filkri specifically eligible only for the Additional Discount Program due to non-TAA compliance. All submissions must be electronically delivered by July 27, 2026, and require active SAM registration, valid CAGE codes, original or electronic signatures, and compliance with the Quote Review Checklist and fully executed signature pages. Participation necessitates affiliation with the DOW Prime Vendor Program and commitment to establish a limited distribution channel with Accredo for TRICARE mail-order fulfillment. Pricing is not tied to fixed quantities but will be loaded into DLA’s electronic pricing system upon contract execution, with payment processed quarterly and due 70 days after utilization data is provided to manufacturers. Failure to meet payment obligations may result in termination of the UF ADP and reconsideration of formulary status. The government reserves the right to evaluate combination agents and multiple formulations as single entities. Trade Agreement Act compliance is the responsibility of DLA, not the offeror, and contracts may be unilaterally terminated if FSS or Big 4 pricing becomes more advantageous, or if FSS interim agreements expire without successor contracts. Performance is governed by agreements effective upon signature, with place of performance in San Antonio, Texas, and invo